Gust J - Search Results

1

How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity.

Santomasso BD, Gust J, Perna F. Santomasso BD, et al. Among authors: gust j. Blood. 2023 May 18;141(20):2443-2451. doi: 10.1182/blood.2022017604. Blood. 2023. PMID: 36877916 Free PMC article.

2

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ. Hay KA, et al. Among authors: gust j. Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18. Blood. 2017. PMID: 28924019 Free PMC article. Clinical Trial.

3

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.

Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC. Gardner RA, et al. Among authors: gust j. Blood. 2019 Dec 12;134(24):2149-2158. doi: 10.1182/blood.2019001463. Blood. 2019. PMID: 31697826 Free PMC article.

4

Cytokines in CAR T Cell-Associated Neurotoxicity.

Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Gust J, et al. Front Immunol. 2020 Dec 16;11:577027. doi: 10.3389/fimmu.2020.577027. eCollection 2020. Front Immunol. 2020. PMID: 33391257 Free PMC article. Review.

5

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.

Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, Wu QV, Park JR, Gardner RA, Annesley CE. Gust J, et al. Blood Adv. 2023 Mar 28;7(6):1001-1010. doi: 10.1182/bloodadvances.2022008119. Blood Adv. 2023. PMID: 36006611 Free PMC article.

6

BCMA-CAR T-cell treatment-associated parkinsonism.

Gust J. Gust J. Blood. 2023 Oct 5;142(14):1181-1183. doi: 10.1182/blood.2023021860. Blood. 2023. PMID: 37796518 No abstract available.

7

Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.

Gust J, Taraseviciute A, Turtle CJ. Gust J, et al. CNS Drugs. 2018 Dec;32(12):1091-1101. doi: 10.1007/s40263-018-0582-9. CNS Drugs. 2018. PMID: 30387077 Free PMC article. Review.

8

EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity.

Gust J, Annesley CE, Gardner RA, Bozarth X. Gust J, et al. J Clin Neurophysiol. 2021 Mar 1;38(2):135-142. doi: 10.1097/WNP.0000000000000669. J Clin Neurophysiol. 2021. PMID: 31851018 Free PMC article. Clinical Trial.

9

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers.

Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales MA. Paczesny S, et al. Among authors: gust j. Blood Adv. 2021 Jun 8;5(11):2519-2522. doi: 10.1182/bloodadvances.2021004604. Blood Adv. 2021. PMID: 34100901 Free PMC article. No abstract available.

10

Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy.

Faulhaber LD, Phuong AQ, Hartsuyker KJ, Cho Y, Mand KK, Harper SD, Olson AK, Garden GA, Shih AY, Gust J. Faulhaber LD, et al. Among authors: gust j. Brain Commun. 2021 Dec 31;4(1):fcab309. doi: 10.1093/braincomms/fcab309. eCollection 2022. Brain Commun. 2021. PMID: 35169706 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page